申请人:Mavunkel J. Babu
公开号:US20070161649A1
公开(公告)日:2007-07-12
The invention is directed to methods to inhibit p38-α kinase using compounds of the formula
and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein
represents a single or double bond;
one Z
2
is CA or CR
8
A and the other is CR
1
, CR
1
2
, NR
6
or N wherein each R
1
, R
6
and R
8
is independently hydrogen or noninterfering substituent;
A is —W
i
—COX
j
Y wherein Y is COR
2
or an isostere thereof and R
2
is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1;
Z
3
is NR
7
or O;
each R
3
is independently a noninterfering substituent; n is 0-3;
each of L
1
and L
2
is a linker;
each R
4
is independently a noninterfering substituent; m is 0-4;
Z
1
is CR
5
or N wherein R
5
is hydrogen or a noninterfering substituent; each of 1 and k is an integer from 0-2 wherein the sum of 1 and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and
the distance between the atom of Ar linked to L
2
and the center of the α ring is 4.5-24 Å.
该发明涉及使用以下式子的化合物及其药学上可接受的盐或药物组合物来抑制p38-α激酶的方法:
其中,表示单键或双键;其中一个Z2为CA或CR8A,另一个为CR1、CR12、NR6或N,其中每个R1、R6和R8都独立地为氢或非干扰基;A为—Wi—COXjY,其中Y为COR2或其同分异构体,R2为氢或非干扰基,W和X均为2-6Å的间隔,i和j均独立地为0或1;Z3为NR7或O;每个R3都是非干扰基;n为0-3;每个L1和L2都是连接基;每个R4都是非干扰基;m为0-4;Z1为CR5或N,其中R5为氢或非干扰基;每个1和k为0-2的整数,其中1和k的和为0-3;Ar为芳基基团,其上带有0-5个非干扰基,其中两个非干扰基可以形成螺环;且与L2连接的Ar原子与α环中心之间的距离为4.5-24Å。